Bristol-Myers Squibb (BMY) Tops Q2 EPS by 3c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bristol-Myers Squibb Reports Second Quarter Financial Results
July 28, 2016 6:59 AM EDTIncreases Second Quarter Revenues 17% to $4.9 Billion Posts Second Quarter GAAP and Non-GAAP EPS of $0.69 Achieves Important Regulatory Milestones in Immuno-Oncology Opdivo + Yervoy Regimen Approved in Europe for Metastatic Melanoma Opdivo Approved in the U.S. for the Treatment of Classical Hodgkin Lymphoma Opdivo Granted Breakthrough Therapy Designation for Advanced Form of Bladder Cancer Empliciti Approved in Europe for Combination Treatment for Multiple Myeloma... More
